Recent Updates
Recently added Catalysts
LTRN Positive Sentiment Score: 75/100

Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers

Thursday, July 23, 2026 1 min read
Key Takeaway: Lantern Pharma has received a Notice of Allowance from the USPTO for its patent application concerning biomarker-guided treatment methods for solid tumor cancers. This patent will enhance the company's ability to develop targeted therapies using its AI and genomic data capabilities. The allowed claims specifically focus on methods for selecting and treating patients with various solid tumors.

Market Sentiment Analysis

POSITIVE FACTORS

  • Lantern Pharma received a Notice of Allowance from the USPTO.
  • The patent covers biomarker-guided treatment methods.
  • This advancement supports targeted therapies for solid tumor cancers.

Full Press Release Details

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence and genomic data to develop targeted cancer therapies, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 17/230,821, titled "Methods for the Treatment of Solid Tumor Cancers Using Illudins and Biomarkers." The allowed claims cover methods of selecting and treating patients with ovar

Frequently Asked Questions

What is the recent patent allowance for Lantern Pharma?

Lantern Pharma received a Notice of Allowance for its patent on biomarker-guided treatment methods.

What does the patent cover?

The patent covers methods for selecting and treating patients with solid tumor cancers.

How does Lantern Pharma develop its therapies?

Lantern Pharma uses artificial intelligence and genomic data to create targeted cancer therapies.

What is LP-184?

LP-184, also known as Zirdafulven, is part of Lantern Pharma's targeted cancer therapy development.

Tags: LTRN Viatris Investor Conferences Healthcare Lantern Pharma biomarker-guided treatment solid tumors LP-184 cancer therapy
Last updated: Jul 23, 2026

Biotech snapshot

Cash runway
$6M liquidity · $1M/mo burn
~3 mo
High dilution risk
Lead asset
LP-184Phase 1
Advanced Solid Tumor →